Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Envoy Medical (COCH) EPS (Weighted Average and Diluted) (2022 - 2025)

Envoy Medical's EPS (Weighted Average and Diluted) history spans 4 years, with the latest figure at -$0.26 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at -$0.26 for Q4 2025, up 35.0% from a year ago — trailing twelve months through Dec 2025 was -$1.22 (up 18.12% YoY), and the annual figure for FY2025 was -$1.23, up 17.45%.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.26 at Envoy Medical, up from -$0.35 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.23 in Q1 2022 to a low of -$1.31 in Q1 2023.
  • The 4-year median for EPS (Weighted Average and Diluted) is -$0.29 (2024), against an average of -$0.31.
  • Peak annual rise in EPS (Weighted Average and Diluted) hit 200.0% in 2023, while the deepest fall reached 669.57% in 2023.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$1.13 in 2022, then skyrocketed by 92.92% to -$0.08 in 2023, then tumbled by 400.0% to -$0.4 in 2024, then surged by 35.0% to -$0.26 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$0.26, -$0.35, and -$0.32 for Q4 2025, Q3 2025, and Q2 2025 respectively.